• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA OKs AtriCure’s AF ablation post-approval study | Regulatory Roundup

FDA OKs AtriCure’s AF ablation post-approval study | Regulatory Roundup

September 17, 2012 By MassDevice staff

 AtriCure wins FDA OK to launch post-approval clinical study of AF ablation
AtriCure (NSDQ:ATRC) won FDA approval to launch a post-approval clinical study of its Synergy radiofrequency ablation system in treatment of non-paroxysmal atrial fibrillation, a chronic and hard-to-treat heart disease.

The new 3-year, 350-patient ABLATE study follows the West Chester, Ohio-based device maker’s December 2011 FDA win for the Synergy ablation system, indicated for treatment of AF during open-heart surgery.

Previous Synergy studies found that 84% of patients were free from AF at 6 month following treatment, and 75% remained AF-free at 22 months.

The device was the 1st surgical ablation system approved by the federal watchdog agency for treating AF (other, catheter-based techniques have already gotten an FDA nod) and the 1st approved for treating persistent and long-standing persistent AF, according to AtriCure. The FDA already cleared the Synergy device for cardiac ablation during concomitant open-heart surgical procedures.

ATRC shares were down 4% to $7.57 as of about 1:30 p.m. today.
Read more

 Sorin wins China regulatory approval for suite of pacemakers
Sorin Group (BIT:SRN) won approval from China’s State Food & Drug Administration for the Reply and Esprit families of pacemakers, which boast some of the industry’s smallest devices and proprietary safety features that prevent unnecessary shocks to the heart.
Read more

 Teleflex touts FDA clearance for latest Arrow catheter
Teleflex (NYSE:TFX) won FDA clearance for the latest in its line of Arrow peripherally inserted central catheter devices, now pre-loaded with the Arrow VPS vascular positioning system. The device replaces chest X-rays by using real-time intravascular Doppler, ECG and advanced algorithms for detecting the location of the catheter tip.
Read more

Filed Under: Food & Drug Administration (FDA), News Well Tagged With: Ablation, AtriCure Inc., Regulatory Roundup

More recent news

  • Alpheus Medical raises $52M for ultrasound-activated tumor therapy
  • Elucent Medical wins FDA breakthrough nod for in-body spatial intelligence system
  • EndoQuest Robotics completes first cases in pivotal surgical robot trial
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Intuitive Surgical is making a CEO change

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy